The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.
Christopher Ryan Heery
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
Marijo Bilusic
No relevant relationships to disclose
Joseph W. Kim
No relevant relationships to disclose
Nishith K. Singh
No relevant relationships to disclose
Myrna Rauckhorst
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose
Clara Chen
No relevant relationships to disclose
Robert S. DiPaola
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose
Dennis Panicali
Employment or Leadership Position - Bavarian Nordic
Stock Ownership - Bavarian Nordic
James W. Hodge
Research Funding - Bavarian Nordic
Jeffrey Schlom
Research Funding - Bavarian Nordic
James L. Gulley
No relevant relationships to disclose